NYMX - Helius Medical: A Failed Clinical Trial Redacted Data And Questionable Leadership Points To An Ineffective Device
We at White Diamond Research like shorting medical device companies with an inefficient product or products. Last year, we exposed Transenterix (TRXC) and Viveve Systems (VIVE) as each has a medical device that is fundamentally flawed.
Our next medical device stock short idea is Helius Medical Technologies (HSDT). It is a pre-revenue, $200M+ market cap company claiming its only product, the Portable Neuromodulation Stimulator (PoNS) device, can treat a type of brain injury by functional electrical stimulation of the tongue. This device is based on a still unproven concept